AU2023267747A1 - Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors - Google Patents

Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors Download PDF

Info

Publication number
AU2023267747A1
AU2023267747A1 AU2023267747A AU2023267747A AU2023267747A1 AU 2023267747 A1 AU2023267747 A1 AU 2023267747A1 AU 2023267747 A AU2023267747 A AU 2023267747A AU 2023267747 A AU2023267747 A AU 2023267747A AU 2023267747 A1 AU2023267747 A1 AU 2023267747A1
Authority
AU
Australia
Prior art keywords
mmol
group
pyrido
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023267747A
Other languages
English (en)
Inventor
Maria DIPOTO
Emily FRIIS
Satenig GULER
Theresa Johnson
Bin Li
Constantin Neagu
Momar TOURE
Andrea Unzue Lopez
Yanping Wang
Yufang Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2023267747A1 publication Critical patent/AU2023267747A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023267747A 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors Pending AU2023267747A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263340191P 2022-05-10 2022-05-10
US63/340,191 2022-05-10
US202263383190P 2022-11-10 2022-11-10
US63/383,190 2022-11-10
PCT/US2023/066601 WO2023220541A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
AU2023267747A1 true AU2023267747A1 (en) 2024-11-07

Family

ID=86688794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023267747A Pending AU2023267747A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Country Status (9)

Country Link
US (1) US20240025922A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522618A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025521083A (cg-RX-API-DMAC7.html)
CN (1) CN119546610A (cg-RX-API-DMAC7.html)
AU (1) AU2023267747A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250387A1 (cg-RX-API-DMAC7.html)
IL (1) IL316818A (cg-RX-API-DMAC7.html)
TW (1) TW202400612A (cg-RX-API-DMAC7.html)
WO (1) WO2023220541A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010302A (es) * 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.

Also Published As

Publication number Publication date
TW202400612A (zh) 2024-01-01
CA3250387A1 (en) 2023-11-16
JP2025521083A (ja) 2025-07-08
IL316818A (en) 2025-01-01
WO2023220541A1 (en) 2023-11-16
CN119546610A (zh) 2025-02-28
US20240025922A1 (en) 2024-01-25
EP4522618A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12233062B2 (en) Heterocyclic derivatives useful as SHP2 inhibitors
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
AU2019216728B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
RU2617405C2 (ru) Пиридоновые и азапиридоновые соединения и способы применения
CN111867590B (zh) Atr激酶的杂环抑制剂
EP4010335A1 (en) Shp2 inhibitors
CA3189912A1 (en) Bicyclic compounds, compositions and use thereof
AU2025226693A1 (en) Monoacylglycerol lipase modulators
MD3483164T2 (ro) Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
EP3601259A1 (en) Isoquinolines as inhibitors of hpk1
EP2945939A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CA2922230A1 (en) Biaryl acetamide compounds and methods of use thereof
CA2821712A1 (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP2023534837A (ja) アンドロゲン受容体モジュレーターとしてのインドール化合物
EP4313983A1 (en) (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
EP4522618A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
TW202440086A (zh) 作為激酶抑制劑之雙環脲
TW202610638A (zh) 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法
BR112014010459B1 (pt) Compostos e composição farmacêutica